Press Release: Xalud : Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress
• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which persists to 180 days following a single injection
Read full article »
Xalud is a New York-based biotechnology firm that develops non-viral gene therapies for the treatment of inflammatory diseases.
Read more